-+ 0.00%
-+ 0.00%
-+ 0.00%

PharmaTher Seeks FDA Orphan Drug Designation for GAMT Deficiency Treatment

PUBT·10/28/2026 12:10:03
Listen to the news
PharmaTher Seeks FDA Orphan Drug Designation for GAMT Deficiency Treatment
  • PharmaTher submitted FDA applications for orphan drug and rare pediatric disease designations for creatine monohydrate to treat GAMT deficiency.
  • FDA designation decisions and a pre-IND meeting are expected in Q1 2027.
  • Product approval could yield a transferable priority review voucher; recent vouchers sold for US$150-200 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmather Holdings Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610280800NEWSFILECNPR____20261028_321351_1) on October 28, 2026, and is solely responsible for the information contained therein.